Efficient tumor transduction and antitumor efficacy in experimental human osteosarcoma using retroviral replicating vectors
この論文をさがす
説明
Retroviral replicating vectors (RRVs) have achieved efficient tumor transduction and enhanced therapeutic benefit in a wide variety of cancer models. Here, we evaluated two different RRVs derived from amphotropic murine leukemia virus (AMLV) and gibbon ape leukemia virus (GALV), which utilize different cellular receptors (PiT-2 and PiT-1, respectively) for viral entry, in human osteosarcoma cells. Quantitative RT-PCR showed that low levels of expression of both receptors were observed in normal and non-malignant cells. However, high PiT-2 (for AMLV) and low PiT-1 (for GALV) expression was observed in most osteosarcoma cell lines. Accordingly, AMLV expressing the green fluorescent protein gene infected and replicated more efficiently than GALV in most osteosarcoma cell lines. Furthermore, RRVs expressing the cytosine deaminase prodrug activator gene showed differential cytotoxicity that correlated with the results of viral spread. AMLV-RRV-mediated prodrug activator gene therapy achieved significant inhibition of subcutaneous MG-63 tumor growth over GALV in nude mice. These data indicate that AMLV vectors predominate over GALV in human osteosarcoma cells. Moreover, our findings support the potential utility of the two RRVs in personalized cancer virotherapy on the basis of receptor expression.
収録刊行物
-
- Cancer Gene Therapy
-
Cancer Gene Therapy 26 (1-2), 41-47, 2018-07-25
Springer Science and Business Media LLC
- Tweet
キーワード
- Pediatric Cancer
- Medical Biotechnology
- Oncology and Carcinogenesis
- Immunology
- Nude
- Gibbon Ape
- Mice, Nude
- Bone Neoplasms
- Article
- Cell Line
- Cytosine Deaminase
- Mice
- Rare Diseases
- Cell Line, Tumor
- Receptors
- Genetics
- 2.1 Biological and endogenous factors
- Animals
- Humans
- Prodrugs
- Oncology & Carcinogenesis
- Aetiology
- Murine
- Cancer
- Pediatric
- Oncolytic Virotherapy
- Osteosarcoma
- Tumor
- Biomedical and Clinical Sciences
- Oncology and carcinogenesis
- Gene Therapy
- Leukemia Virus
- Xenograft Model Antitumor Assays
- Virus
- Leukemia Virus, Murine
- Orphan Drug
- Treatment Outcome
- Leukemia Virus, Gibbon Ape
- Receptors, Virus
- Female
- Biotechnology
詳細情報 詳細情報について
-
- CRID
- 1360567183415557120
-
- ISSN
- 14765500
- 09291903
-
- PubMed
- 30042500
-
- 資料種別
- journal article
-
- データソース種別
-
- Crossref
- KAKEN
- OpenAIRE